B-Cell Lymphoma

The DIRECT molecular monitoring platform - identifying patients suitable for novel agent clinical trials (STAGE1).

DIRECT: Clinical Investigator

Dr Daniel Hodson

Read More Arrow

The aim of the DIRECT Study is to establish a robust pipeline to identify those patients with high-grade B cell lymphoma most suitable for novel agent clinical trials based upon genomic subtype and an integrated response evaluation determined early in first-line therapy.

This will be done by integrating data and samples collected from patients undergoing standard of care treatment for high-grade B cell lymphoma.

The trial is being funded jointly by AstraZeneca and the Cancer Research UK Cambridge Centre as well as being a flagship trial for MFICM. The trial currently has a total of 72 patients recruited over 5 sites as follows:

Addenbrooke’s Hospital                                                          20

University Hospitals Leicester                                                20

Norfolk & Norwich University Hospital                                 19

Northwest Anglia NHS Foundation Trust                             2

Nottingham University Hospital                                             11

Data will be integrated from

  1. Clinical risk factors from the International Prognostic Index (IPI)
  2. Up-front genomic subtype based on molecular profiling of diagnostic biopsy
  3. Serial ctDNA monitoring during treatment.
  4. Radiological response imaging

Clinical trial registration

 

 

Connect

Connect with us

The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.

Find out more

Connect